Detalhe da pesquisa
1.
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
Br J Clin Pharmacol
; 83(5): 1072-1081, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28138980
2.
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
Ann Intern Med
; 174(3): 431-432, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721528
3.
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Int J Clin Pharmacol Ther
; 53(2): 129-38, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25500487
4.
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Int J Clin Pharmacol Ther
; 53(3): 256-64, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25546166
5.
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Int J Clin Pharmacol Ther
; 53(6): 438-46, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907176
6.
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Int J Clin Pharmacol Ther
; 53(1): 41-53, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25345427
7.
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Int J Clin Pharmacol Ther
; 53(2): 115-28, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25407255
8.
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Drug Metab Dispos
; 42(5): 903-16, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24568888
9.
Clinical Pharmacology Perspective on Development of Adeno-Associated Virus Vector-Based Retina Gene Therapy.
Clin Pharmacol Ther
; 115(6): 1212-1232, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450707
10.
Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Sci Rep
; 11(1): 11066, 2021 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34040108
11.
Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.
Antimicrob Agents Chemother
; 52(10): 3478-83, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18644951
12.
Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
J Clin Pharmacol
; 47(4): 497-509, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17389559
13.
Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Sci Rep
; 12(1): 5740, 2022 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35388049
14.
Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
Clin Ther
; 38(1): 89-98.e1, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26687552
15.
Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
Clin Pharmacokinet
; 55(2): 209-23, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26293616
16.
Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Clin Pharmacokinet
; 54(10): 1027-41, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26041408
17.
Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
Clin Pharmacol Drug Dev
; 4(4): 279-86, 2015 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27136908
18.
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Clin Ther
; 37(7): 1483-1492.e1, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26048186
19.
In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
J Clin Pharmacol
; 55(9): 1061-72, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25827774
20.
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Clin Ther
; 37(3): 610-628.e4, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25659911